HC Wainwright & Co. Maintains Buy on Genmab, Raises Price Target to $70

Benzinga · 3d ago
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Genmab (NASDAQ:GMAB) with a Buy and raises the price target from $50 to $70.